Company Overview and News

1
Lithium Miners News For The Month Of March 2018

2018-03-26 seekingalpha
Lithium spot and contract price news - Lithium spot prices were stable, while 2018 LCE global contract prices are about 20% higher than 2017.
Upvote Downvote

1
Traka Resources exercises option over Gorge Creek cobalt prospect

2018-01-05 proactiveinvestors.com.au
Traka Resources Ltd (ASX:TKL) has exercised its option to the polymetallic Gorge Creek Project located to the northern extent of the Queensland Northern Territory border.
Upvote Downvote

 
Traka Resources leverages itself to highly prospective Mt Isa Inlier and Carpentaria Province

2017-11-26 proactiveinvestors.com.au
Traka Resources Ltd (ASX:TKL) recently reached an agreement with a private company, Cobalt QLD Pty Ltd, on the Gorge Creek Project.
Upvote Downvote

 
Traka Resources' shares surf higher on proximity to Quicksilver nickel-cobalt discovery

2017-11-19 proactiveinvestors.com.au
Traka Resources Ltd (ASX:TKL) shares soared 74% to $0.073 intra-day on Friday compared to the previous sessions lows, before the company received an ASX speeding ticket in the form of a price query.
Upvote Downvote

 
3 Small Gold Explorers Worth Less Than Their Liquidation Value

2017-01-18 seekingalpha
The 3 companies in this article are worth less than their liquidation value, with assets ranging from cash to shares to JV and exploration properties.
Upvote Downvote

 
Traka confirms Mt Short base metals

2016-05-03 news.theage.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.
Upvote Downvote

 
Traka confirms Mt Short base metals

2016-05-03 news.smh.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.
Upvote Downvote

 

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...